-
Mashup Score: 1From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts - 1 year(s) ago
Cancer-associated fibroblasts (CAFs) are one of the major cell components in the tumor stroma (see Glossary) of solid cancers, playing a key role within the tumor microenvironment (TME) [1,2]. CAFs are heterogeneous and comprise subsets that differ from each other in phenotype, function, transcriptional program, and cell of origin [3–10] (Box 1).
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Clinical Development of BRAF plus MEK Inhibitor Combinations - 1 year(s) ago
Genomic profiling shows that many solid tumors are characterized by specific driver aberrations, and this has expanded the therapeutic options for many patients. The mitogen-activated protein kinase (MAPK) pathway is a key cell signaling pathway involved in regulating cellular growth, proliferation, and survival. Driver mutations in the BRAF gene, a key player in the MAPK pathway, are described…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Impact of tissue-agnostic approvals for patients with sarcoma - 1 year(s) ago
Tissue-agnostic drug development is a major step forward in offering treatment options for rare tumors. Sarcomas are heterogeneous rare malignancies with more than 100 subtypes. Recent failure of Phase III trials, nonbiomarker-driven clinical trials, and rarity hamper developmental therapeutics in sarcomas. Since a ‘one-size-fits-all’ approach continues to be the standard of care, tissue-agnostic…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Gastrointestinal (GI) malignancies encompass a broad range of tumors with limited treatment options, particularly for advanced disease. With the development and implementation of next-generation sequencing (NGS) in routine practice, molecular-targeting therapies have been increasingly incorporated into the treatment paradigm for various cancers. Several drugs have achieved tissue-agnostic…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
Gastrointestinal (GI) malignancies encompass a broad range of tumors with limited treatment options, particularly for advanced disease. With the development and implementation of next-generation sequencing (NGS) in routine practice, molecular-targeting therapies have been increasingly incorporated into the treatment paradigm for various cancers. Several drugs have achieved tissue-agnostic…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Gastrointestinal (GI) malignancies encompass a broad range of tumors with limited treatment options, particularly for advanced disease. With the development and implementation of next-generation sequencing (NGS) in routine practice, molecular-targeting therapies have been increasingly incorporated into the treatment paradigm for various cancers. Several drugs have achieved tissue-agnostic…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 10
Precision medicine has exploited next-generation sequencing (NGS) and gene/immune-targeted drug deployment to transform the outlook for several lethal cancers. For instance, there are now several FDA-approved medications that target the sequelae of aberrant genes in a tissue-agnostic approach: pembrolizumab [microsatellite instability and tumor mutational burden (TMB) ≥10 mutations/megabase…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Impact of tissue-agnostic approvals for patients with sarcoma - 1 year(s) ago
Tissue-agnostic drug development is a major step forward in offering treatment options for rare tumors. Sarcomas are heterogeneous rare malignancies with more than 100 subtypes. Recent failure of Phase III trials, nonbiomarker-driven clinical trials, and rarity hamper developmental therapeutics in sarcomas. Since a ‘one-size-fits-all’ approach continues to be the standard of care, tissue-agnostic…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5
Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who do not benefit from IO, instead experiencing rapid progression with dramatic acceleration of disease trajectory, termed ‘hyperprogressive disease’ (HPD). The incidence of HPD ranges from 4% to 29% from the studies reported. Biological basis…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized drug combinations, rather than one-size-fits-all monotherapy. The raison-d’être…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts https://t.co/ZsPQwl6Bu2